SIC 2833 – Medicinal Chemicals and Botanical Products
| Valuation | |
|---|---|
| Market Cap ($M) | 143.44 |
| Enterprise Value ($M) | 152.02 |
| Book Value ($M) | 36.13 |
| Book Value / Share | 3.92 |
| Price / Book | 3.97 |
| NCAV ($M) | -4.26 |
| NCAV / Share | -0.46 |
| Price / NCAV | -33.66 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.18 |
| Return on Assets (ROA) | 0.16 |
| Return on Equity (ROE) | 0.31 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.62 |
| Current Ratio | 1.60 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 18.14 |
| Assets | 58.53 |
| Liabilities | 22.41 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 64.47 |
| Operating Income | 13.37 |
| Net Income | 8.98 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 9.61 |
| Cash from Investing | -0.01 |
| Cash from Financing | -6.98 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Askeladden Capital Management Llc | 5.40 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 2,120 | 16,281 | 13.02 | |
| 4,955 | 41,963 | 11.81 | |
| 807 | 8,612 | 9.37 | |
| 4,013 | 26,036 | 15.41 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| FBRX – Forte Biosciences, Inc. | FENC – Fennec Pharmaceuticals Inc. |
| FLGC – Flora Growth Corp. | GALT – Galectin Therapeutics Inc. |
| GDTC – CytoMed Therapeutics Limited |
Financial data and stock pages provided by
Fintel.io